Association Between HbA1c Levels on Adverse Pregnancy Outcomes During Pregnancy in Patients With Type 1 Diabetes.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
17 02 2022
Historique:
received: 14 05 2021
pubmed: 26 10 2021
medline: 3 3 2022
entrez: 25 10 2021
Statut: ppublish

Résumé

Despite optimization of metabolic balance during pregnancy in type 1 diabetes (T1D), maternal-fetal complications remain higher than in the background population. We examined whether there is an association between glycated hemoglobin (HbA1c) levels and these complications. Retrospective study of pregnancies in 678 T1D subjects at Lille Hospital (1997-2019). The association between variations in HbA1c levels and complications was examined. The composite criterion (CC) was defined as having at least 1 of the following complications: prematurity, pre-eclampsia, large for gestational age (LGA), small for gestational age (SGA), or cesarean section. Among the 678 births, median preconception HbA1c was 7.2% (55 mmol/mol), 361 were LGA (56%), 29 were SGA (4.5%), and 504 were births without preterm delivery (76.1%). The CC occurred in 81.8%. Higher HbA1c during the first trimester was associated with the CC (OR 1.04; 95% CI 1.02-1.06 per 0.1% increase; P < .001). Higher HbA1c during the third trimester was associated with the CC (OR 1.07; 95% CI 1.03-1.10 per 0.1% increase; P < .001). The group defined by a first trimester Hba1c >6.5% (48 mmol/mol) and a third trimester HbA1c <6% was associated with an increased rate of the CC (OR 2.81; 95% CI 1.01-7.86) and an increased rate of LGA (OR 2.20; 95% CI 1.01- 4.78). Elevated HbA1c is associated with maternal-fetal complications. Despite optimization of metabolic balance during the third trimester, for patients with early glycemic imbalance the risk of LGA persists.

Identifiants

pubmed: 34694409
pii: 6409789
doi: 10.1210/clinem/dgab769
pmc: PMC8852207
doi:

Substances chimiques

Glycated Hemoglobin A 0
hemoglobin A1c protein, human 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1117-e1125

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.

Références

J Clin Endocrinol Metab. 2022 Feb 17;107(3):e1117-e1125
pubmed: 34694409
Med J Aust. 2016 Aug 15;205(4):162-7
pubmed: 27510344
J Matern Fetal Neonatal Med. 2018 Jul;31(14):1933-1939
pubmed: 28574296
J Diabetes Complications. 2014 Mar-Apr;28(2):203-7
pubmed: 24268941
Bratisl Lek Listy. 2017;118(1):56-60
pubmed: 28127984
Lancet. 2017 Nov 25;390(10110):2347-2359
pubmed: 28923465
Diabetologia. 2018 May;61(5):1012-1021
pubmed: 29356835
Diabetes Metab Syndr. 2012 Jan-Mar;6(1):59-64
pubmed: 23014257
Obes Rev. 2019 Aug;20(8):1106-1120
pubmed: 31090253
Clin Chim Acta. 2018 Mar;478:57-61
pubmed: 29274326
Diabetes Care. 2021 Jan;44(Suppl 1):S200-S210
pubmed: 33298425
Diabetes Metab. 2012 Jun;38(3):205-16
pubmed: 22521040
Obstet Gynecol Surv. 2004 Aug;59(8):628-36
pubmed: 15277897
BMC Pregnancy Childbirth. 2015 Mar 27;15:69
pubmed: 25885892
Lancet Diabetes Endocrinol. 2021 Mar;9(3):153-164
pubmed: 33516295
J Matern Fetal Neonatal Med. 2016;29(14):2252-8
pubmed: 26364952
Clin Chem Lab Med. 2011 Nov 26;50(5):905-9
pubmed: 22117781
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Diabetes Res Clin Pract. 2019 Apr;150:202-210
pubmed: 30880095
Neth J Med. 2013 Jan;71(1):22-5
pubmed: 23412819
Diabetes Technol Ther. 2018 Jun;20(6):413-419
pubmed: 29901410
Immunobiology. 2019 Mar;224(2):334-338
pubmed: 30819511
Diabetes Metab Syndr. 2019 Jan - Feb;13(1):84-88
pubmed: 30641818
J Gynecol Obstet Biol Reprod (Paris). 1996;25(1):61-70
pubmed: 8901304
J Natl Med Assoc. 1993 Jul;85(7):537-45
pubmed: 8350376
Diabetes Care. 2006 Dec;29(12):2612-6
pubmed: 17130193
Diabetes Care. 2018 Aug;41(8):1821-1828
pubmed: 30030258
Diabet Med. 1990 May;7(4):360
pubmed: 2140091
Diabetes Metab. 2019 Apr;45(2):191-196
pubmed: 29776801

Auteurs

Madleen Lemaitre (M)

Department of Diabetology, Endocrinology, Metabolism, and Nutrition, CHU Lille, Lille University Hospital, Lille, France.
Department of Medicine, University of Lille, France.

Camille Ternynck (C)

, ULR 2694-METRICS: évaluation des technologies de santé et des pratiques médicales, University of Lille, CHU Lille, Lille, France.
Department of Biostatistics, CHU Lille, Lille, France.

Julien Bourry (J)

Department of Diabetology, Endocrinology, Metabolism, and Nutrition, CHU Lille, Lille University Hospital, Lille, France.
Department of Medicine, University of Lille, France.

Florence Baudoux (F)

Department of Diabetology, Endocrinology, Metabolism, and Nutrition, CHU Lille, Lille University Hospital, Lille, France.

Damien Subtil (D)

Department of Medicine, University of Lille, France.
Department of Gynecology and Obstetrics, CHU Lille, Lille University Hospital, Lille, France.

Anne Vambergue (A)

Department of Diabetology, Endocrinology, Metabolism, and Nutrition, CHU Lille, Lille University Hospital, Lille, France.
Department of Medicine, University of Lille, France.
European Genomic Institute for Diabetes, University School of Medicine, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH